Management review is next week. ISO 13485 5.6 requires external signal data as input. Your team hasn't gathered it yet, and you're staring at a blank slide for the board report on risk exposure and co

Here's what's happening right now: There were 10,384 new regulatory signals today, including 10,360 FDA Adverse Event Reports (MAUDE/MDRs) and 22 Health Canada mdl entries. Notably, Health Canada issued 2 new recalls: Auro-Canagliflozin for incorrect DIN labeling and LUXA-D for a foreign product in a capsule, both flagged for product safety.

For your management review under QMSR and 21 CFR 820, this data isn't just noise—it's critical for quantifying risk exposure and benchmarking against competitors. The pattern of labeling errors and contamination in recalls highlights systemic supply chain or manufacturing issues that could impact your own product portfolio. Without this context, your board reporting lacks the external validation required by ISO 13485 5.6, potentially leaving gaps in risk mitigation strategies.

We analyzed this across 548,000+ regulatory records and found that such signals often cluster by device category, allowing for targeted risk assessments and proactive compliance adjustments. This depth of data transforms reactive monitoring into strategic foresight for your quality system.

See how your specific product codes compare to these emerging risks at truemeddevice.com.